Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice.
Carol H WyshamDavida F KrugerPublished in: Journal of the Endocrine Society (2021)
Use of continuous glucose monitoring (CGM) has been shown to improve clinical outcomes in patients with type 1 diabetes (T1D) and type 2 diabetes (T2D), including improved glycemic control, better treatment adherence, and an increased understanding of their treatment regimens. Retrospective analysis of CGM data allows clinicians and patients to identify glycemic patterns that support and facilitate informed therapy adjustments. There are currently 2 types of CGM systems: real-time CGM (rtCGM) and flash CGM. The FreeStyle Libre 2 (FSL2) is the newest flash CGM system commercially available. Because the FSL2 system was only recently cleared for use in the US, many endocrinologists and diabetes specialists may be unfamiliar with the strengths, limitations, and potential of the FSL2 system. This article focuses on practical approaches and strategies for initiating and using flash CGM in endocrinology and diabetes specialty practices.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- cardiovascular disease
- weight loss
- clinical practice
- end stage renal disease
- insulin resistance
- primary care
- chronic kidney disease
- healthcare
- palliative care
- ejection fraction
- prognostic factors
- newly diagnosed
- risk assessment
- adipose tissue
- electronic health record
- peritoneal dialysis
- replacement therapy
- metabolic syndrome
- cell therapy